To combine or not to combine? A literature review of antidepressant combination therapy

被引:73
作者
Dodd, S
Horgan, D
Malhi, GS
Berk, M
机构
[1] Univ Melbourne, Dept Clin & Biomed Sci, Swanston Ctr, Geelong, Vic 3220, Australia
[2] Univ Melbourne, Dept Psychiat, Parkville, Vic, Australia
[3] Univ New S Wales, Sch Psychiat, Mood Disorders Unit, Black Dog Inst, Sydney, NSW, Australia
[4] Orygen Res Ctr, Parkville, Vic, Australia
关键词
depression; treatment resistance; augmentation; antidepressant; serotonin; interaction; polypharmacy;
D O I
10.1016/j.jad.2005.08.012
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Treatment resistant depression is a common clinical problem and a major public health concern. The use of antidepressant combinations to overcome treatment resistance, while somewhat controversial, is a popular strategy in practice. This paper reviews published trials on combination antidepressants with a view to inform clinical practice. Method: A systematic but selective review of the published literature was conducted using EMBASE, PSYCHLIT and MEDLINE with relevant search terms. Results: A number of trials suggesting efficacy of combination antidepressants were found. These are incorporated into a number of treatment guidelines for the management of treatment refractory depression. Clinicians should be cautious regarding pharmacokinetic and pharmacodynamic interactions, including the serotonin syndrome, however combination strategies are an effective option. Conclusions: Many antidepressants can be usefully combined especially if they engage separate mechanisms of action. Clinically, antidepressant combinations provide a useful resort in otherwise treatment resistant individuals. However, much further research is needed to determine relative efficacy and determine long term outcome. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:1 / 11
页数:11
相关论文
共 63 条
[1]   Suicide attempts, age and duration of illness in recurrent affective disorders [J].
Ahrens, B ;
Berghofer, A ;
Wolf, T ;
MullerOerlinghausen, B .
JOURNAL OF AFFECTIVE DISORDERS, 1995, 36 (1-2) :43-49
[2]  
Amsterdam J D, 1997, Depress Anxiety, V5, P84, DOI 10.1002/(SICI)1520-6394(1997)5:2<84::AID-DA4>3.3.CO
[3]  
2-N
[4]   MOCLOBEMIDE AND SPECIFIC SEROTONIN REUPTAKE INHIBITOR COMBINATION TREATMENT OF RESISTANT ANXIETY AND DEPRESSIVE-DISORDERS [J].
BAKISH, D ;
HOOPER, CL ;
WEST, DL ;
MILLER, C ;
BLANCHARD, A ;
BASHIR, F .
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 1995, 10 (02) :105-109
[5]   A 3-YEAR FOLLOW-UP OF A GROUP OF TREATMENT-RESISTANT DEPRESSED-PATIENTS WITH A MAOI TRICYCLIC COMBINATION [J].
BERLANGA, C ;
ORTEGASOTO, HA .
JOURNAL OF AFFECTIVE DISORDERS, 1995, 34 (03) :187-192
[6]   Non response to citalopram in depressive patients: Pharmacokinetic and clinical consequences of a fluvoxamine augmentation [J].
Bondolfi, G ;
Chautems, C ;
Rochat, B ;
Bertschy, G ;
Baumann, P .
PSYCHOPHARMACOLOGY, 1996, 128 (04) :421-425
[7]   Mirtazapine augmentation in the treatment of refractory depression [J].
Carpenter, LL ;
Jocic, Z ;
Hall, JM ;
Rasmussen, SA ;
Price, LH .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (01) :45-+
[8]   A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine [J].
Carpenter, LL ;
Yasmin, S ;
Price, LH .
BIOLOGICAL PSYCHIATRY, 2002, 51 (02) :183-188
[9]   The Texas Medication Algorithm Project: Report of the Texas Consensus Conference Panel on medication treatment of major depressive disorder [J].
Crismon, ML ;
Trivedi, M ;
Pigott, TA ;
Rush, AJ ;
Hirschfeld, RMA ;
Kahn, DA ;
DeBattista, C ;
Nelson, JC ;
Nierenberg, AA ;
Sackeim, HA ;
Thase, ME .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (03) :142-156
[10]  
DAVIDSON J, 1978, ARCH GEN PSYCHIAT, V35, P639